SCHEMBL7120211

SCHEMBL7120211

CC(C)Cc1c(O)c2cc(Cl)ccc2[nH]c1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
MAPT P10636 1/20 0.62
GRIN2D O15399 2/20 0.55
GRIN3B O60391 2/20 0.55
GRIN1 Q05586 2/20 0.55
GRIN2A Q12879 2/20 0.55
GRIN2B Q13224 2/20 0.55
GRIN2C Q14957 2/20 0.55
GRIN3A Q8TCU5 2/20 0.55
KDM4E B2RXH2 6/20 0.52
GSK3B P49841 2/20 0.45
LMNA P02545 2/20 0.44
HPGD P15428 3/20 0.43
HSD17B10 Q99714 1/20 0.43
DAO P14920 1/20 0.43
CYP1A2 P05177 1/20 0.43
GAA P10253 1/20 0.43
SIRT1 Q96EB6 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7552688 0.89 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AMAPTGRIN2D
SCHEMBL7114815 0.84 ALDH1A1 (0.67) ALDH1A1MEN1KMT2AMAPTGRIN2D
SCHEMBL7124017 0.83 KDM4E (0.46) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL7116460 0.82 ALDH1A1 (0.65) ALDH1A1MEN1KMT2AMAPTGRIN2D
SCHEMBL7119094 0.79 MEN1 (0.43) ALDH1A1MEN1KMT2AMAPTGRIN2D
SCHEMBL7122454 0.78 GRIN2D (0.58) ALDH1A1MEN1KMT2AMAPTGRIN2D
SCHEMBL7118635 0.77 GRIN2D (0.53) ALDH1A1MEN1KMT2AMAPTGRIN2D
SCHEMBL7118690 0.75 MEN1 (0.40) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL23259127 0.75 HTR7 (0.60) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL404810 0.73 GRIN2D (0.63) ALDH1A1MEN1KMT2AMAPTGRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 ALDH1A1 1742/4885MEN1 3110/4885KMT2A 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.